ES2172288T3 - Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. - Google Patents

Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.

Info

Publication number
ES2172288T3
ES2172288T3 ES99303729T ES99303729T ES2172288T3 ES 2172288 T3 ES2172288 T3 ES 2172288T3 ES 99303729 T ES99303729 T ES 99303729T ES 99303729 T ES99303729 T ES 99303729T ES 2172288 T3 ES2172288 T3 ES 2172288T3
Authority
ES
Spain
Prior art keywords
patients
infection
ribavirina
interfered
understands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99303729T
Other languages
English (en)
Inventor
Janice K Albrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2172288(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2172288T3 publication Critical patent/ES2172288T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE PRESENTA EL USO DE RIBAVIRIN Y DE LA INTERFERONA ALFA PARA PREPARAR COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE PACIENTES INFANTILES EN TRATAMIENTO ANTIVIRAL QUE TENGAN INFECCION CRONICA POR HEPATITIS C PARA ERRADICAR EL VCH-ARN DETECTABLE QUE COMPRENDE UNA TERAPIA COMBINACIONAL QUE UTILIZA UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE RIBAVIRIN Y UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE INTERFERONA ALFA DURANTE UN PERIODO DE ENTRE 20 Y 50 SEMANAS.
ES99303729T 1998-05-15 1999-05-13 Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. Expired - Lifetime ES2172288T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
ES2172288T3 true ES2172288T3 (es) 2002-09-16

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99303729T Expired - Lifetime ES2172288T3 (es) 1998-05-15 1999-05-13 Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.

Country Status (23)

Country Link
EP (3) EP0956861B1 (es)
JP (2) JP5281726B2 (es)
KR (1) KR100694345B1 (es)
CN (1) CN1230198C (es)
AR (1) AR019551A1 (es)
AT (1) ATE216591T1 (es)
AU (2) AU766597B2 (es)
BR (1) BR9910505A (es)
CA (1) CA2331823A1 (es)
CZ (1) CZ300540B6 (es)
DE (1) DE69901321T2 (es)
DK (1) DK0956861T3 (es)
ES (1) ES2172288T3 (es)
HK (1) HK1021131A1 (es)
HU (1) HU230432B1 (es)
IL (3) IL139220A0 (es)
MY (1) MY129244A (es)
NO (1) NO330715B1 (es)
NZ (1) NZ507621A (es)
PT (1) PT956861E (es)
SK (1) SK288038B6 (es)
TW (1) TWI277424B (es)
WO (1) WO1999059621A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2157000A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
EP1244356A4 (en) * 1999-12-23 2003-03-19 Icn Pharmaceuticals COMPOSITIONS AND METHODS RELATING TO NUCLEOSIDES-L, NUCLEOTIDES-L AND THEIR ANALOGS
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7662798B2 (en) 2002-06-28 2010-02-16 Idenix Pharmaceuticals, Inc. 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
US20050049204A1 (en) * 2003-03-28 2005-03-03 Otto Michael J. Compounds for the treatment of flaviviridae infections
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
US20070026014A1 (en) * 2003-04-17 2007-02-01 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
SI2604620T1 (sl) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modificirani fluorirani nukleozidni analogi
US7482149B2 (en) * 2003-06-09 2009-01-27 Genome Institute Of Singapore Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
CA2535451A1 (en) * 2003-08-13 2005-02-24 Howard J. Smith & Associates Pty Ltd. Method of treating viral infections
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
TW201424733A (zh) * 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
AP2907A (en) 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2175865A4 (en) 2007-07-25 2012-01-11 Biolex Therapeutics Inc INTERFERON DRUG PRODUCTS WITH CONTROLLED RELEASE AND TREATMENT OF HCV INFECTIONS THEREWITH
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
HUE034239T2 (en) 2010-03-31 2018-02-28 Gilead Pharmasset Llc Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
WO2012045704A1 (en) * 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG10201706949VA (en) 2013-01-31 2017-09-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2329474C (en) * 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
ATE206618T1 (de) * 1997-09-21 2001-10-15 Schering Corp Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infektion

Also Published As

Publication number Publication date
NZ507621A (en) 2002-11-26
AU2005220271A1 (en) 2005-11-03
DE69901321D1 (de) 2002-05-29
JP5281726B2 (ja) 2013-09-04
DE69901321T2 (de) 2002-12-12
MY129244A (en) 2007-03-30
TWI277424B (en) 2007-04-01
AU3860099A (en) 1999-12-06
BR9910505A (pt) 2001-01-02
IL207259A (en) 2016-08-31
CN1309568A (zh) 2001-08-22
AU2005220271B2 (en) 2005-11-03
KR100694345B1 (ko) 2007-03-12
CZ300540B6 (cs) 2009-06-10
ATE216591T1 (de) 2002-05-15
DK0956861T3 (da) 2002-07-01
EP0956861A1 (en) 1999-11-17
EP0956861B1 (en) 2002-04-24
NO330715B1 (no) 2011-06-20
HU230432B1 (hu) 2016-06-28
HK1021131A1 (en) 2000-06-02
EP1213029A1 (en) 2002-06-12
SK17102000A3 (sk) 2001-05-10
AU2005220271B9 (en) 2010-12-09
WO1999059621A1 (en) 1999-11-25
AU766597B2 (en) 2003-10-16
CZ20004177A3 (cs) 2001-04-11
HUP0103423A3 (en) 2003-11-28
HUP0103423A2 (hu) 2002-01-28
IL139220A (en) 2013-02-28
CA2331823A1 (en) 1999-11-25
JP2002515453A (ja) 2002-05-28
PT956861E (pt) 2002-08-30
NO20005755L (no) 2001-01-12
EP2305287A1 (en) 2011-04-06
CN1230198C (zh) 2005-12-07
NO20005755D0 (no) 2000-11-14
IL139220A0 (en) 2001-11-25
SK288038B6 (en) 2013-01-02
AU2005220271B8 (en) 2010-11-18
AR019551A1 (es) 2002-02-27
JP2011173898A (ja) 2011-09-08
IL207259A0 (en) 2010-12-30
KR20010043624A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
ES2172288T3 (es) Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
YU79393A (sh) Terapeutska kombinacija
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
YU63002A (sh) Formulacija male doze entekavira i upotreba
AR023541A1 (es) Terapia de combinacion para vhc
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
BR0108997A (pt) Terapia imune adjuvante para hiv
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
PT1049480E (pt) Agente herbaceo antiviral
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
AR013424A1 (es) Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina
CO5170404A1 (es) Terapia para melanomas
MD1609G2 (ro) Metodă de tratament al stomatitei aftoase recidivante cronice
IT1229361B (it) Dispositivo per alleviare i disagi del corpo umano durante il suo stazionamento in posizioni obbligate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 956861

Country of ref document: ES